Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Potestio

Showing results (41-50 of 138) with videos related to

Pageof 14
Sort By:
Clinical and Experimental Dermatology|December 18, 2024
The use of ChatGPT in the dermatological field: a narrative reviewLuca Potestio, Federica Feo, Fabrizio Martora, et al.
International Journal of Molecular Sciences|June 24, 2022
The Treatment of Advanced Melanoma: Therapeutic UpdateAlessia Villani, Luca Potestio, Gabriella Fabbrocini, et al.
Clinical, Cosmetic and Investigational Dermatology|January 15, 2024
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative ReviewLuca Potestio, Fabrizio Martora, Sara Cacciapuoti, et al.
Dermatology and Therapy|July 21, 2023
The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular AreaAlessia Villani, Gabriella Fabbrocini, Giuseppe Micali, et al.
Clinical, Cosmetic and Investigational Dermatology|November 17, 2022
Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current LiteratureFabrizio Martora, Teresa Battista, Claudio Marasca, et al.
Journal of Clinical Medicine|May 11, 2024
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life StudyMatteo Megna, Angelo Ruggiero, Fabrizio Martora, et al.
Expert Opinion on Drug Safety|May 24, 2023
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluationAngelo Ruggiero, Luca Potestio, Fabrizio Martora, et al.
Clinical, Cosmetic and Investigational Dermatology|March 6, 2023
Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective StudyAngelo Ruggiero, Gabriella Fabbrocicni, Sara Cacciapuoti, et al.
Clinical, Cosmetic and Investigational Dermatology|September 25, 2025
Guselkumab In A Subset Of Multifailure Patients With Hidradenitis Suppurativa: Real-Word Evidence from Federico IIFabrizio Martora, Nello Tommasino, Luigi Coronella, et al.
Medicina (Kaunas, Lithuania)|September 28, 2024
Hidradenitis Suppurativa in Elderly Patients: Clinical and Therapeutical Outcomes-A Review of the LiteratureFabrizio Martora, Nello Tommasino, Claudio Brescia, et al.
Pageof 14

Showing results (41-50 of 138) with videos related to

Sort By:
Pageof 14
Clinical and Experimental Dermatology|December 18, 2024
The use of ChatGPT in the dermatological field: a narrative reviewLuca Potestio, Federica Feo, Fabrizio Martora, et al.
International Journal of Molecular Sciences|June 24, 2022
The Treatment of Advanced Melanoma: Therapeutic UpdateAlessia Villani, Luca Potestio, Gabriella Fabbrocini, et al.
Clinical, Cosmetic and Investigational Dermatology|January 15, 2024
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative ReviewLuca Potestio, Fabrizio Martora, Sara Cacciapuoti, et al.
Dermatology and Therapy|July 21, 2023
The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular AreaAlessia Villani, Gabriella Fabbrocini, Giuseppe Micali, et al.
Clinical, Cosmetic and Investigational Dermatology|November 17, 2022
Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current LiteratureFabrizio Martora, Teresa Battista, Claudio Marasca, et al.
Journal of Clinical Medicine|May 11, 2024
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life StudyMatteo Megna, Angelo Ruggiero, Fabrizio Martora, et al.
Expert Opinion on Drug Safety|May 24, 2023
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluationAngelo Ruggiero, Luca Potestio, Fabrizio Martora, et al.
Clinical, Cosmetic and Investigational Dermatology|March 6, 2023
Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective StudyAngelo Ruggiero, Gabriella Fabbrocicni, Sara Cacciapuoti, et al.
Clinical, Cosmetic and Investigational Dermatology|September 25, 2025
Guselkumab In A Subset Of Multifailure Patients With Hidradenitis Suppurativa: Real-Word Evidence from Federico IIFabrizio Martora, Nello Tommasino, Luigi Coronella, et al.
Medicina (Kaunas, Lithuania)|September 28, 2024
Hidradenitis Suppurativa in Elderly Patients: Clinical and Therapeutical Outcomes-A Review of the LiteratureFabrizio Martora, Nello Tommasino, Claudio Brescia, et al.
Pageof 14